Maddy summaryThe Protecting Our Kids from Harmful Research Act prohibits the use of federal funds to support research or publications regarding gender transition for individuals under the age of 18. This restriction specifically targets studies that aim to affirm a minor's perception or identity when it differs from their sex assigned at birth, as defined by their reproductive biology and genetics. The bill directly affects federal agencies and institutions that might otherwise receive funding to conduct such observational studies on hormonal treatments or surgical procedures for minors. By limiting financial support, the legislation seeks to prevent government resources from being used for research that challenges the biological definition of sex at birth.
Sponsored bills
Maddy summaryThe Citizenship for International Adoptees Act of 2026 grants automatic U.S. citizenship to individuals born outside the United States who were adopted by U.S. citizens before turning 18 and have lived in the country since the law takes effect. To qualify, applicants must have been legally adopted, meet specific residency requirements, and demonstrate a commitment to the U.S. by being physically present in the country on the enactment date. The bill also establishes a fee cap for these applications, setting the cost at no more than half the standard fee for a certificate of citizenship. However, the law excludes individuals with certain criminal convictions, including those involving domestic violence, sexual abuse, burglary, or membership in criminal gangs, as well as those deemed inadmissible or deportable under existing immigration rules.
Maddy summaryThe Audit the Pentagon Act requires the Department of Defense to reduce its funding by 2 percent if it fails to receive a clean financial audit for a given year. This penalty applies to all departments, agencies, and elements within the Pentagon starting after fiscal year 2024. The withheld money is distributed proportionally across various programs and projects, while the remaining funds are sent to the Treasury to help reduce the national deficit.
Maddy summaryThe Federal Insurance Office Abolishment Act of 2026 eliminates the Federal Insurance Office within the Department of the Treasury and removes the position of its Director. This legislation amends existing laws to delete references to the office and its director, ensuring that related financial regulatory powers remain with the Secretary of the Treasury. By striking specific sections in the Dodd-Frank Act and other statutes, the bill clarifies that oversight of insurance matters will continue under the Treasury Secretary's authority without the dedicated office. The changes directly affect the organizational structure of federal financial regulation by removing a specific entity while preserving the underlying legal authority of the Treasury Department.
Maddy summaryThis bill amends the Mineral Leasing Act to change how bonus payments are made for specific coal leases. Under the new rules, the total bonus amount would be split into ten equal annual payments instead of being paid all at once. The first installment must be submitted with the initial bid, while the remaining nine payments are due over the following nine years. This provision directly affects companies bidding for coal leases and the government agencies managing those leases.
Maddy summaryThe Daughters of the American Revolution Membership Integrity Act amends federal law to explicitly define membership eligibility for the organization. It requires that members be women, legally defined as adult human females who possess a reproductive system capable of producing ova for fertilization. This provision clarifies the genealogical and biological qualifications needed to join the group while maintaining its existing membership structure.
Maddy summaryThe Arctic Security and Diplomacy Act establishes a new framework to counter espionage and influence operations by foreign adversaries, specifically targeting Russia and China, in the Arctic region. It requires the Secretary of State to create a national strategy and mandates that foreign scientists obtain prior U.S. government approval before conducting marine scientific research in U.S. waters. The law also prohibits the U.S. from approving research applications for vessels owned or operated by foreign adversaries, with limited exceptions for national interest, and requires regular reports to Congress on these security threats.
Maddy summaryThe CLEAR LABELS Act (S 3788) requires drug manufacturers, packers, and distributors to label finished drugs and active pharmaceutical ingredients with specific supply chain information. This includes the name, location, and unique facility ID of the original manufacturer for both active ingredients and finished products, either directly on labels or via QR codes/link to an electronic portal. The bill directly affects drug companies and distributors by mandating clearer labeling to trace products through the supply chain. It also exempts compliant drugs from separate customs country-of-origin marking requirements. These changes aim to improve transparency for consumers and regulators about drug origins.
Maddy summaryThis bill simplifies the approval process for biosimilar drugs - medicines that are highly similar to, but not identical to, existing biologic drugs. It amends the Public Health Service Act to clarify when biosimilars are deemed "interchangeable" with the original drug (allowing pharmacists to substitute them without a doctor's specific order), adjusts exclusivity periods for existing biosimilars, and sets a 60-day transition period after enactment. The bill also requires the FDA to update its guidance documents within 18 months to reflect these changes. This directly affects pharmaceutical companies developing biosimilars, the FDA in its review process, and ultimately patients seeking more affordable treatment options.
Maddy summaryThis bill modifies requirements for approving biosimilar drugs (follow-on versions of biologic medicines). It removes previous mandatory assessments of immunogenicity or clinical efficacy for biosimilar licensure, instead allowing the FDA to require such studies only when the agency provides written justification to the applicant. The change applies to new biosimilar applications submitted after the bill's enactment. It directly affects drug manufacturers seeking FDA approval for biosimilars and the FDA's review process, aiming to streamline approvals while maintaining safety standards.